Key Highlights
•
A new, brief questionnaire called BE-PSD-V2.0 is a reliable and much faster tool for assessing symptoms in schizophrenia, showing strong agreement with the longer, more complex tests doctors currently use. This means clinicians can monitor patient symptoms more efficiently, potentially leading to quicker adjustments in treatment plans.
Source →
•
A study of multiple sclerosis relapses found that most patients (94%) recover from a relapse, but the process can take up to a year, challenging the idea that disability progression measured at 3 or 6 months is permanent. This finding suggests that recovery is slower than previously thought, which could change how doctors measure treatment success in clinical trials.
Source →
•
A new screening strategy combining a brief memory test with a simple blood test for Alzheimer’s disease (plasma p-tau217) was successfully implemented in a community health screening program in China. This practical approach could enable earlier detection of Alzheimer’s in large populations, especially in areas with limited medical resources.
Source →
•
Researchers are studying the “no-reflow” phenomenon, where blood flow fails to return to brain tissue even after a successful clot removal procedure for stroke. Understanding the timing and dynamics of this problem on MRI scans is crucial for developing new treatments to protect the brain in the critical hours after a stroke.
Source →
•
A global panel of experts has reached a consensus on the best strategies to prevent relapse in patients with major depression who have successfully been treated with electroconvulsive therapy (ECT). This provides much-needed guidance for psychiatrists on how to maintain the benefits of this powerful treatment over the long term.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
